Abstract
Atopic dermatitis (AD) is a prevalent chronic inflammatory skin condition with an unpredictable clinical course, associated with a significant impact on quality of life. The pathophysiology of AD involves a complex interplay between impaired skin barrier function, immune dysregulation, genetic susceptibility and environmental factors. Advances in understanding of the immunological mechanisms that underpin AD have heralded the recognition of multiple novel therapeutic targets to bolster the systemic treatment armamentarium for patients with severe AD. This review examines current and future directions of non-biologic systemic treatments for AD, with a focus on their mechanism of action, efficacy and safety, and the key considerations to help inform treatment decisions. We summarize new developments in small molecule systemic therapies which have the potential to further advance our management of AD in this new era of precision medicine.
| Original language | English |
|---|---|
| Pages (from-to) | 495-510 |
| Number of pages | 16 |
| Journal | Clinical and Experimental Allergy |
| Volume | 53 |
| Issue number | 5 |
| DOIs | |
| Publication status | Published - May 2023 |
Keywords
- atopic dermatitis
- Janus kinase inhibitors
- small molecule inhibitors
- systemic treatment
